Update of EULAR recommendations for the treatment of systemic sclerosis

The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. Update of the previous treatment recommendations was performed according to EULAR standard operating procedures. The task force consisted of 32 SSc clinical experts from Europe and the USA, 2 patients nominated by the pan-European patient association for SSc (Federation of European Scleroderma Associations (FESCA)), a clinical epidemiologist and 2 research fellows. All centres from the EULAR Scleroderma Trials and Research group were invited to submit and select clinical questions concerning SSc treatment using a Delphi approach. Accordingly, 46 clinical questions addressing 26 different interventions were selected for systematic literature review. The new recommendations were based on the available evidence and developed in a consensus meeting with clinical experts and patients. The procedure resulted in 16 recommendations being developed (instead of 14 in 2009) that address treatment of several SSc-related organ complications: Raynaud's phenomenon (RP), digital ulcers (DUs), pulmonary arterial hypertension (PAH), skin and lung disease, scleroderma renal crisis and gastrointestinal involvement. Compared with the 2009 recommendations, the 2016 recommendations include phosphodiesterase type 5 (PDE-5) inhibitors for the treatment of SSc-related RP and DUs, riociguat, new aspects for endothelin receptor antagonists, prostacyclin analogues and PDE-5 inhibitors for SSc-related PAH. New recommendations regarding the use of fluoxetine for SSc-related RP and haematopoietic stem cell transplantation for selected patients with rapidly progressive SSc were also added. In addition, several comments regarding other treatments addressed in clinical questions and suggestions for the SSc research agenda were formulated. These updated data-derived and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc.

[1]  M. Baron,et al.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial , 2016, The Lancet.

[2]  Dual and Dual Investigators,et al.  Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. , 2016, JAMA.

[3]  R. Jaussaud,et al.  Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study , 2015, Annals of the rheumatic diseases.

[4]  M. Camilleri,et al.  Prokinetics in gastroparesis. , 2015, Gastroenterology clinics of North America.

[5]  M. Dougados,et al.  2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations , 2014, Annals of the rheumatic diseases.

[6]  H. Palevsky,et al.  Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. , 2014, Chest.

[7]  B. Griffiths,et al.  Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. , 2014, JAMA.

[8]  M. Hudson,et al.  Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. , 2014, Seminars in arthritis and rheumatism.

[9]  C. Denton,et al.  Current management strategies for systemic sclerosis. , 2014, Clinical and experimental rheumatology.

[10]  G. Valentini,et al.  Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries , 2014, Clinical Rheumatology.

[11]  L. Scott,et al.  Riociguat: First Global Approval , 2013, Drugs.

[12]  M. Mayes,et al.  2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative , 2013, Annals of the rheumatic diseases.

[13]  K. Whelan,et al.  Review article: small intestinal bacterial overgrowth – prevalence, clinical features, current and developing diagnostic tests, and treatment , 2013, Alimentary pharmacology & therapeutics.

[14]  J. Pope,et al.  Meta‐Analysis of Healing and Prevention of Digital Ulcers in Systemic Sclerosis , 2013, Arthritis care & research.

[15]  Z. Jing,et al.  Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[16]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[17]  M. Numans,et al.  Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. , 2013, The Cochrane database of systematic reviews.

[18]  M. Roustit,et al.  Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials , 2013, Annals of the rheumatic diseases.

[19]  N. Vakil.  Prescribing Proton Pump Inhibitors , 2012, Drugs.

[20]  J. Hoenderop,et al.  Systematic review: hypomagnesaemia induced by proton pump inhibition , 2012, Alimentary pharmacology & therapeutics.

[21]  M. Hellmich,et al.  Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. , 2012, Archives of internal medicine.

[22]  L. Mouthon,et al.  Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. , 2012, Rheumatology.

[23]  D. Wuttge,et al.  Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor , 2012, Scandinavian journal of rheumatology.

[24]  W. Haefeli,et al.  Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. , 2011, International journal of cardiology.

[25]  Sanjiv J. Shah,et al.  Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial , 2011, The Lancet.

[26]  J. Pope,et al.  Expert Agreement on EULAR/EUSTAR Recommendations for the Management of Systemic Sclerosis , 2011, The Journal of Rheumatology.

[27]  E. Quigley,et al.  Cisapride: What can we learn from the rise and fall of a prokinetic? , 2011, Journal of digestive diseases.

[28]  Jonathan G. Goldin,et al.  Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. , 2011, Arthritis and rheumatism.

[29]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[30]  N. Tamimi,et al.  Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. , 2011, Arthritis and rheumatism.

[31]  P. Shenoy,et al.  Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. , 2010, Rheumatology.

[32]  R. Elashoff,et al.  Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. , 2009, Chest.

[33]  W. Tierney,et al.  Long-term safety concerns with proton pump inhibitors. , 2009, The American journal of medicine.

[34]  P. Ducrotte,et al.  Small intestinal bacterial overgrowth in systemic sclerosis. , 2009, Rheumatology.

[35]  J. Seibold,et al.  Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud’s Phenomenon Secondary to Systemic Sclerosis , 2009, The Journal of Rheumatology.

[36]  C. Denton,et al.  Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? , 2009, Clinical and experimental rheumatology.

[37]  R. Landewé,et al.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) , 2009, Annals of the rheumatic diseases.

[38]  G. Tomlinson,et al.  Shifting Our Thinking About Uncommon Disease Trials: The Case of Methotrexate in Scleroderma , 2008, The Journal of Rheumatology.

[39]  R. Landewé,et al.  European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research , 2008, Annals of the rheumatic diseases.

[40]  E. Savarino,et al.  Small Intestinal Bacterial Overgrowth in Patients Suffering From Scleroderma: Clinical Effectiveness of Its Eradication , 2008, The American Journal of Gastroenterology.

[41]  R. Elashoff,et al.  Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. , 2007, American journal of respiratory and critical care medicine.

[42]  C. Denton,et al.  Scleroderma renal crisis: patient characteristics and long-term outcomes. , 2007, QJM : monthly journal of the Association of Physicians.

[43]  L. Mouthon,et al.  Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients , 2007, Annals of the rheumatic diseases.

[44]  P. Sfikakis,et al.  Treatment of Small Intestinal Disease in Systemic Sclerosis With Octreotide: A Prospective Study in Seven Patients , 2007, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[45]  P. Emery,et al.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.

[46]  C. Ricachinevsky,et al.  Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.

[47]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.

[48]  M. Böhm,et al.  Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy , 2005, Circulation.

[49]  M. Mayes,et al.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. , 2004, Arthritis and rheumatism.

[50]  F Guillemin,et al.  EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees , 2004, Annals of the rheumatic diseases.

[51]  W. Hasler.  Pharmacotherapy for intestinal motor and sensory disorders. , 2003, Gastroenterology clinics of North America.

[52]  Richard W. Martin,et al.  Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. , 2002, Arthritis and rheumatism.

[53]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[54]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[55]  T. Hsieh,et al.  Effects of Cisapride on Oesophageal Transit of Solids in Patients with Progressive Systemic Sclerosis , 2002, Clinical Rheumatology.

[56]  S. Marshall,et al.  Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. , 2001, Rheumatology.

[57]  R. Scorza,et al.  Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. , 2001, Clinical and experimental rheumatology.

[58]  V. Welch,et al.  Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. , 2001, Arthritis and rheumatism.

[59]  N. Bellamy,et al.  A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. , 2001, Arthritis and rheumatism.

[60]  T. Medsger,et al.  Long-Term Outcomes of Scleroderma Renal Crisis , 2000, Annals of Internal Medicine.

[61]  M. Vayssairat.  Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. , 1999, The Journal of rheumatology.

[62]  R. Madhok,et al.  Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. , 1998, British journal of rheumatology.

[63]  T. Medsger,et al.  Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. , 1998, Arthritis and rheumatism.

[64]  A. Silman,et al.  Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. , 1998, The Cochrane database of systematic reviews.

[65]  Richard W. Martin,et al.  Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. , 1998, Arthritis and rheumatism.

[66]  G. Cannon,et al.  Methotrexate pulmonary toxicity. , 1997, Rheumatic diseases clinics of North America.

[67]  R. Hunt,et al.  Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. , 1997, Gastroenterology.

[68]  J. Lynch,et al.  Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. , 1997, American journal of respiratory and critical care medicine.

[69]  F. V. D. van den Hoogen,et al.  Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. , 1996, British journal of rheumatology.

[70]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[71]  C. Sninsky,et al.  Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction , 1995, Digestive Diseases and Sciences.

[72]  R. Madhok,et al.  Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. , 1995, Annals of the rheumatic diseases.

[73]  A. Morelli,et al.  Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. , 1994, The American journal of gastroenterology.

[74]  L. Kaufman,et al.  Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study , 1994, Annals of Internal Medicine.

[75]  B. Hazleman,et al.  Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. , 1992, The Journal of rheumatology.

[76]  W. Hasler,et al.  Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. , 1991, The New England journal of medicine.

[77]  B. Amor,et al.  The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study. , 1991, British journal of clinical pharmacology.

[78]  J. Costantino,et al.  Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. , 1990, Annals of internal medicine.

[79]  W. Caspary,et al.  [Effect of cisapride on esophageal motility in healthy probands and patients with progressive systemic scleroderma]. , 1990, Klinische Wochenschrift.

[80]  T. Wehrmann,et al.  Einfluß von Cisaprid auf die Oesophagusmotilität bei Gesunden und Patienten mit progressiver systemischer Sklerodermie , 1990, Klinische Wochenschrift.

[81]  T. Medsger,et al.  Normotensive renal failure in systemic sclerosis. , 1989, Arthritis and rheumatism.

[82]  J. Kirby,et al.  Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. , 1989, BMJ.

[83]  D. Isenberg,et al.  Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue. , 1988, British journal of rheumatology.

[84]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[85]  E. Ring,et al.  Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. , 1988, Annals of the rheumatic diseases.

[86]  S. Bowcock,et al.  Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis , 1987, The British journal of dermatology.

[87]  G. Maddern,et al.  Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. , 1987, Gastroenterology.

[88]  B. Amor,et al.  Nicardipine in the Treatment of Raynaud's Phenomenon: A Randomized Double-Blind Trial , 1987, Angiology.

[89]  B. Amor,et al.  Nifedipine and alpha1-adrenergic blockade in Raynaud‘s phenomenon , 1985 .

[90]  W. Ettinger,et al.  Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. , 1984, The American journal of medicine.

[91]  B. Amor,et al.  Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon). , 1983, European heart journal.

[92]  R. Rodeheffer,et al.  Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. , 1983, The New England journal of medicine.

[93]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[94]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[95]  J. Laragh,et al.  Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. , 1979, The New England journal of medicine.

[96]  C. O. Kennedy.  A controlled trial , 1971, British Homeopathic Journal.

[97]  Bibliographic Sources,et al.  Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report , 2017 .

[98]  J. Vachiéry,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[99]  K. McKeage,et al.  Macitentan: First Global Approval , 2013, Drugs.

[100]  R. Scorza,et al.  Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. , 2013, Clinical and experimental rheumatology.

[101]  M. Court-Payen,et al.  Imaging in juvenile idiopathic arthritis with a focus on ultrasonography. , 2013, Clinical and experimental rheumatology.

[102]  V. Prus.  [Digital ulcers in systemic sclerosis]. , 2010, Reumatizam.

[103]  G. Moneta.  Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis , 2010 .

[104]  P. Moayyedi,et al.  Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. , 2005, The Cochrane database of systematic reviews.

[105]  D. Badesch,et al.  Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. , 2000, Annals of internal medicine.

[106]  R. Madhok,et al.  A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. , 1993, Clinical and experimental rheumatology.

[107]  R. Wise,et al.  Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. , 1992, The Journal of rheumatology.

[108]  J. Kleibeuker,et al.  Effects of cisapride on the esophageal motor function of patients with progressive systemic sclerosis or mixed connective tissue disease. , 1991, Digestion.

[109]  B. Amor,et al.  Nifedipine and alpha 1-adrenergic blockade in Raynaud's phenomenon. , 1985, European heart journal.

[110]  M. Matucci-Cerinic,et al.  Extended Report , 2022 .

[111]  and treatment of , 2022 .